Better science. Better results.

Consult with our experts

With over 20 yearsā€™ experience as a Preclinical CRO, CBI has a range of oncology and tumor models suitable for your unique study needs.

  • Angiogenesis, gene therapy, nanoparticle and stem cell capabilities
  • Maximization of test article effectiveness and minimum effective dosage
  • Combination therapies
  • Comparison of formulation and routes of administration
  • Maximum tolerated dose and pharmacokinetics/pharmacodynamics (MTD and PK/PD studies)
  • Validated cell lines include but are not limited to:
    • Breast: MDA-MB-231, MCF-7, 4T1
    • Colon: Caco-2, HCT-116, COL 205, L5174T
    • Lung: A549, Lewis Lung
    • Prostate: LNCAP, PC-3, DU-145
  • PDX models and other translational models
    • Major Oncology Institute Collaborations

Our full service in vivo facility also offers:

  • Toxicology and pharmacokinetic assessments
  • On-site histopathology lab
  • Immunohistochemistry
  • Tissue cross reactivity studies
  • In-house board-certified pathologist
  • Efficient, quality reporting

Extensive experience with

  • Small molecules
  • Biologics
  • Immunotherapy
  • Stem cells
  • Devices and implants
  • Gene therapy

Standards of excellence

  • GLP equipped
  • AAALAC accredited
  • USDA, FDA, and OLAW compliant

Consult with our experts

Fill out the form below to learn more about our oncology capabilities